Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 311

1.

Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.

Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA.

Osteoporos Int. 2011 Mar;22(3):943-54. doi: 10.1007/s00198-010-1309-z. Epub 2010 Jun 8.

2.

Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.

Lin TC, Yang CY, Yang YH, Lin SJ.

J Clin Endocrinol Metab. 2013 Dec;98(12):4717-26. doi: 10.1210/jc.2013-1877. Epub 2013 Sep 30.

PMID:
24081731
3.

Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.

Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Solomon DH.

Ann Intern Med. 2008 May 6;148(9):637-46.

4.

Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.

Curtis JR, Yun H, Lange JL, Matthews R, Sharma P, Saag KG, Delzell E.

Arthritis Care Res (Hoboken). 2012 Dec;64(12):1855-63. doi: 10.1002/acr.21759.

5.
6.

Medical treatment of vertebral osteoporosis.

Lippuner K.

Eur Spine J. 2003 Oct;12 Suppl 2:S132-41. Epub 2003 Sep 17. Review.

7.

Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.

Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY.

Osteoporos Int. 2008 Jun;19(6):811-8.

PMID:
17999022
8.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
9.

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM.

Osteoporos Int. 2010 Nov;21(11):1943-51. doi: 10.1007/s00198-009-1134-4. Epub 2009 Dec 5. Review.

PMID:
19967338
10.

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Wang Z, Ward MM, Chan L, Bhattacharyya T.

Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x. Epub 2014 May 21.

11.

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T.

Osteoporos Int. 2010 Jun;21(6):1021-9. doi: 10.1007/s00198-009-1046-3. Epub 2009 Sep 1.

12.

Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.

Shalev V, Sharman Moser S, Goldshtein I, Yu J, Weil C, Ish-Shalom S, Rouach V, Chodick G.

Ann Pharmacother. 2017 Sep;51(9):757-767. doi: 10.1177/1060028017710482. Epub 2017 May 23.

PMID:
28535690
13.

Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.

Lin TC, Lee CH, Yang CY, Yang YH, Lin SJ.

J Clin Endocrinol Metab. 2014 May;99(5):1599-607. doi: 10.1210/jc.2013-3114. Epub 2014 Feb 25.

PMID:
24606074
14.
15.

Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.

Hernandez I, Zhang Y.

J Eval Clin Pract. 2015 Oct;21(5):840-7. doi: 10.1111/jep.12389. Epub 2015 Jun 9.

PMID:
26059485
16.

Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.

Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, Diakun DR, Krege JH.

BMC Womens Health. 2013 Mar 23;13:15. doi: 10.1186/1472-6874-13-15.

17.

Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.

Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH.

J Bone Miner Res. 2011 May;26(5):993-1001. doi: 10.1002/jbmr.288.

18.

Hip fractures in users of first- vs. second-generation bisphosphonates.

Mamdani M, Kopp A, Hawker G.

Osteoporos Int. 2007 Dec;18(12):1595-600. Epub 2007 Sep 1.

PMID:
17767369
19.

Fractures and mortality in relation to different osteoporosis treatments.

Yun H, Delzell E, Saag KG, Kilgore ML, Morrisey MA, Muntner P, Matthews R, Guo L, Wright N, Smith W, Colón-Emeric C, O'Connor CM, Lyles KW, Curtis JR.

Clin Exp Rheumatol. 2015 May-Jun;33(3):302-9. Epub 2014 Jul 28.

20.

Use of anti-osteoporotic drugs in central Norway after a forearm fracture.

Hoff M, Skurtveit S, Meyer HE, Langhammer A, Søgaard AJ, Syversen U, Abrahamsen B, Schei B.

Arch Osteoporos. 2015;10:235. doi: 10.1007/s11657-015-0235-2. Epub 2015 Sep 3.

PMID:
26334427

Supplemental Content

Support Center